MARKET PULSE- Facebook, AMD, Netflix, Merck, Newmont Mining, Mannkind

(For more market insights, including options activity, click on
; for the Day Ahead newsletter http://link.reuters.com/mex49s)

Wall Street was set for a lower open on Monday, focused on
events in Washington after weekend talks between Republicans and
Democrats showed some progress but left alive the risk of a
possible U.S. default in three days, pressuring stocks. S&P 500
futures fell 12.5 points and were below fair value, a
formula that evaluates pricing by taking into account interest
rates, dividends and time to expiration on the contract. Dow
Jones industrial average futures fell 106 points and
Nasdaq 100 futures lost 19.25 points.

** FACEBOOK INC (NasdaqGS: FB - news) , Friday close $49.11, down 1.5 pct
premarket

The social networking company said it would buy start-up
app-maker Onavo, the Israeli firm said on its website, without
giving any details of the deal. Facebook is paying between $150
million and $200 million, the Calcalist financial news website
reported, making it the social media company's biggest
acquisition in Israel (Other OTC: IRLCF - news) .

** NETFLIX INC (NasdaqGS: NFLX - news) , Friday close $300.84, up 3 pct
premarket

The company is in talks with several U.S. cable television
companies including Comcast Corp and Suddenlink
Communications to make its streaming video service available
through their set-top boxes, the Wall Street Journal reported on
Sunday, citing people familiar with the matter.

** MERCK & CO INC, Friday close 47.29, down 1 pct
premarket

The German drugs and healthcare group is in talks
with external investors including private equity firms to share
the cost of some clinical trials, the Financial Times reported,
citing a senior manager at the company.

** ADVANCED MICRO DEVICES (NYSE: AMD - news) , Friday close $3.83, up 1
pct premarket

Brokerage Wedbush Securities upgraded the chipmaker's stock
to "outperform" from "neutral," saying AMD will benefit from the
launch of gaming consoles in the near term. The brokerage also
expects the company to gain market share in servers. Wedbush
raised its price target on the stock to $5.00 from $4.50.

** NEWMONT MINING CORP, Friday close $25.62, up 1
pct premarket

HSBC Securities raised its price target on the gold miner's
stock to $37.30 from $36.50, maintaining its "overweight"
rating.

Spot gold prices rose 0.7 percent to $1,281.96 an
ounce by 1135 GMT on Monday as the U.S. fiscal impasse remained
unresolved.

** ARCELORMITTAL SA, Friday close $14.91, up 2.21 pct
premarket

Analysts at Macquarie Equities Research raised their rating
on the world's largest steelmaker's stock to "outperform" from
"neutral," according to Theflyonthewall.com.

** EXPEDIA INC (NasdaqGS: EXPE - news) , Friday close $51.73, down 2 pct
premarket

Deutsche Bank (LSE: 0H7D.L - news) cut its rating on the online travel agency's
stock to "hold" from "buy," according to Theflyonthewall.com.

** PEABODY ENERGY CORP (NYSE: BTU - news) , Friday close $17.40

The company said it had temporarily shut down operations at
its Metropolitan coal mine in Queensland, Australia, pre-empting
a planned strike by workers after a stand-off over a new
employment contract.

** TORONTO-DOMINION BANK, Friday close $89.35

The Canadian bank is considering an 8 billion pound ($13
billion) bid for Royal Bank of Scotland (LSE: RBS.L - news) 's American
retail banking business Citizens (NYSE: CIA - news) , The Sunday Times reported,
without citing sources.

** GENERAL MOTORS CO, Friday close $35.35, down 1 pct
premarket

** TESLA MOTORS INC (Xetra: A1CX3T - news) , Friday close $178.70, up 1.6
pct premarket

General Motors (NYSE: GM - news) will go head to head with electric car maker
Tesla Motors starting in January, when a plug-in version of its
luxury Cadillac brand will go on sale. GM said its 2014 Cadillac
ELR plug-in coupe will have a starting price of almost $76,000
including delivery fees - putting it in competition with the
similarly priced Tesla Model S.

** SUPERIOR ENERGY SERVICES INC (NYSE: SPN - news) , Friday close
$25.87, down 3 pct premarket

The oilfield services company said it expected third-quarter
earnings to fall to between 39 cents and 41 cents per share from
59 cents a year earlier due to a slowdown in land drilling in
the United States. Superior Energy also said its board
authorized a share buyback program of up to $400 million.

** MANNKIND CORP (NasdaqGM: MNKD - news) , Friday close $5.11, up 3.3 pct
premarket

The drugmaker resubmitted the application for approval to
its insulin therapy, Afrezza, to the U.S. health regulator based
on clinical development data, including the results of two
recent late-stage trials in patients with type 1 and type 2
diabetes, respectively.

The drug device, designed to improve glycemic control,
comprises the Afrezza inhalation powder and an inhaler to
administer it.

** GILEAD SCIENCES INC (NasdaqGS: GILD - news) , Friday close $62.69

Leerink Swann raised its price target on the drugmaker's
stock to $77 from $70, saying it was adding $1 billion to its
previous 2014 sales estimate of $2 billion for the company's
chronic hepatitis C drug, sofosbuvir. Leerink analysts cited a
large market opportunity for sofosbuvir in treating hepatitis C
virus infection in liver transplant patients.

** ARATANA THERAPEUTICS INC (NasdaqGM: PETX - news) , Friday close $23.49

The pet medication products maker said it would buy
privately-held Vet Therapeutics Inc in cash and stock to expand
in products to treat lymphoma in dogs. The company will pay $30
million in cash and issue about 625,000 shares to buy Vet
Therapeutics.

** THERAVANCE INC (NasdaqGS: THRX - news) , Friday close $36.27

Cowen and Co analysts said a panel of respiratory experts
at its Therapeutic Categories conference were enthusiastic about
Theravance's respiratory drugs, including Anoro, which they
expect "will take significant share away from drugs such as
Boehringer's Spiriva." The analysts said they now expected sales
of Theravance and GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's co-developed
drugs, Breo and Anoro, to grow to $3 billion and $2.4 billion,
respectively, by 2018.

** ARIAD PHARMACEUTICALS INC (NasdaqGS: ARIA - news) , Friday close $4.26,
down 0.7 pct after market

The U.S. Food and Drug Administration said it is
investigating an increasing number of reports of serious and
life-threatening adverse events in patients taking the company's
leukemia drug, Iclusig.

(Compiled by Sneha Banerjee in Bangalore; Editing by Kirti
Pandey)

Source: http://news.yahoo.com/market-pulse-facebook-amd-netflix-132112158.html
Similar Articles: james franco   aaron hernandez   Payday 2